AU2021227227A1 - Cannabinoid compositions - Google Patents

Cannabinoid compositions Download PDF

Info

Publication number
AU2021227227A1
AU2021227227A1 AU2021227227A AU2021227227A AU2021227227A1 AU 2021227227 A1 AU2021227227 A1 AU 2021227227A1 AU 2021227227 A AU2021227227 A AU 2021227227A AU 2021227227 A AU2021227227 A AU 2021227227A AU 2021227227 A1 AU2021227227 A1 AU 2021227227A1
Authority
AU
Australia
Prior art keywords
cbga
pharmaceutical composition
cannabinoid
acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021227227A
Other languages
English (en)
Inventor
Malika FAOUZI
Ram P. NEUPANE
Reinhold Penner
Sayuri SUZUKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens Medical Center
Original Assignee
Queens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens Medical Center filed Critical Queens Medical Center
Publication of AU2021227227A1 publication Critical patent/AU2021227227A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/28—Cannabaceae, e.g. cannabis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021227227A 2020-02-25 2021-02-24 Cannabinoid compositions Abandoned AU2021227227A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981424P 2020-02-25 2020-02-25
US62/981,424 2020-02-25
US202063072806P 2020-08-31 2020-08-31
US63/072,806 2020-08-31
PCT/US2021/019474 WO2021173718A1 (en) 2020-02-25 2021-02-24 Cannabinoid compositions

Publications (1)

Publication Number Publication Date
AU2021227227A1 true AU2021227227A1 (en) 2022-10-13

Family

ID=77490171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021227227A Abandoned AU2021227227A1 (en) 2020-02-25 2021-02-24 Cannabinoid compositions

Country Status (6)

Country Link
US (1) US20230091336A1 (https=)
EP (1) EP4110045A4 (https=)
JP (1) JP2023527612A (https=)
AU (1) AU2021227227A1 (https=)
CA (1) CA3172868A1 (https=)
WO (1) WO2021173718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
EP4415697A4 (en) * 2021-10-13 2025-08-20 Portland Tech Holdings Llc HEMP EXTRACT FOR THE TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2026038872A1 (ko) * 2024-08-13 2026-02-19 주식회사 네오켄바이오 신규한 화합물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US10857107B2 (en) * 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
EP3592346A4 (en) * 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
JP2020520966A (ja) * 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
US10751380B2 (en) * 2018-03-08 2020-08-25 Alexander Kariman Compound and method for treating spasms, inflammation and pain
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
JP2021524465A (ja) * 2018-05-22 2021-09-13 ジービーエス グローバル バイオファーマ，インコーポレイテッド Ｔｒｐｖ１モジュレーションに使用するためのカンナビノイド及び／又はテルペン
EP3813823A4 (en) * 2018-06-28 2022-08-10 Canopy Growth Corporation COMPOSITIONS AND METHODS FOR AGONIZING THE CB2 RECEPTOR

Also Published As

Publication number Publication date
WO2021173718A1 (en) 2021-09-02
US20230091336A1 (en) 2023-03-23
EP4110045A1 (en) 2023-01-04
JP2023527612A (ja) 2023-06-30
EP4110045A4 (en) 2024-06-05
CA3172868A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US20230091336A1 (en) Cannabinoid compositions
JP6621501B2 (ja) 新規癌治療法としてのアリール炭化水素受容体（ＡｈＲ）改変物質
US20230172899A1 (en) Cannabinoid compositions
Tai et al. In vitro culture studies of Sutherlandia frutescens on human tumor cell lines
JP4993523B2 (ja) ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用
DE602004012279T2 (de) Katecholderivate zur behandlung von krebs
Li et al. Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway
Li et al. Polyamines in the brain: distribution, biological interactions, and their potential therapeutic role in brain ischaemia
US10272093B2 (en) Use of H3K9me3 modulation for enhancing cognitive function
CN109700811B (zh) 吲哚乙酰胺结构类型雄激素受体拮抗剂及其应用
Yang et al. Promising anti-ovarian aging herbal formulation He's Yangchao promotes in vitro maturation of oocytes from advanced maternal age mice
US20240197817A1 (en) Compositions for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof
RU2858979C2 (ru) Антидепрессивное и анксиолитическое замещенное соединение циннамамид
US20240217946A1 (en) Antidepressant and anxiolytic substituted cinnamamide compound
US20210128520A1 (en) Neuroprotective isoflavone compositions and methods
HK40077420A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
US20180221329A1 (en) Cis- and trans-suffruticosol d as therapeutic agents

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period